Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXS196 in Metastatic Uveal Melanoma
NCT02601378Phase 1Terminated
- Sponsor
- Novartis
- Start
- Feb 2016
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of darovasertib in Uveal melanoma (UM) (2 arms), sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities at Cycle 1, Incidence and severity of adverse events and 1 more. Started Feb 2016; status: terminated.
02
Drugs
darovasertib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02601378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601378.